This trial is evaluating whether ChAd155-RG will improve 13 primary outcomes and 3 secondary outcomes in patients with Rabies. Measurement will happen over the course of Day 1 through Day 22.
This trial requires 43 total participants across 4 different treatment groups
This trial involves 4 different treatments. ChAd155-RG is the primary treatment being studied. Participants will be divided into 3 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
Participation is compensated
You will be compensated for participating in this trial.
"Rabies is a deadly disease that kills over a million people annually and is caused by a virus that is transmitted by a bite from a bite infected animal. In the United States, rabid animals are most commonly skunks, stray cats and raccoons.\n" - Anonymous Online Contributor
"The rabies virus lives in the saliva of infected animals and is a potential means of transmission of the disease. Transmission can occur by bites or saliva transmission.\n" - Anonymous Online Contributor
"Of the six therapies described, only nerve grafting and nerve graft plus antiviral therapy resulted in survival. Nerve grafting was the only therapy to result in full recovery. Nerve grafting, which has been shown to be effective in some other species, and the antiviral therapy may, by analogy, be considered first-line therapies to treat rabies." - Anonymous Online Contributor
"An estimated 2,500 deaths have been associated with rabies annually in the United States. Rabies is most commonly contracted through a bite from an infected animal. Most cases occur in children from the age of 4 to 10 years old. The number of cases of human rabies in the United States is decreasing, probably due to public education and increased awareness of rabies. This article demonstrates the steps a community can take to prevent rabies through rabies vaccination programs." - Anonymous Online Contributor
"Rabies can be easily, safely, and quickly eradicated by a human antibody. Rabies was eradicated from a domestic cat in as little as 24 hours. This should be expected to occur in all patients treated with an experimental rabies treatment in clinical trials of a human rabies vaccine. Rabies can be quickly, safely, and successfully eradicated by a neutralizing human monoclonal antibody, once the rabies virus is in the process of entering into the central nervous system." - Anonymous Online Contributor
"The symptoms of rabies are a combination of the symptoms of other diseases with rabies. The initial symptoms after exposure to the infectious agent are generally nonspecific. Fever, headache, chills, and malaise are common, but a headache more often persists than others. Later, a series of neurological symptoms develops. These may precede, follow, or be concomitant with the onset of skin signs. Other symptoms may develop in isolation. The pattern of neurological involvement in rabies may vary. Different features such as the signs and symptoms of stroke are associated with stroke, stroke in association with encephalitis or meningitis due to infectious causes, or in the presence of an underlying infection." - Anonymous Online Contributor
"Recent findings of the current study add further credence to the hypothesis of a genetic basis for rabies transmission. The family histories may be the result of selection among the first generation of families or of genetic drift." - Anonymous Online Contributor
"These data show that the live vaccinia/rabies vaccine is more effective than a placebo and can be used in combination with chemotherapy to enhance the effect of the rabies vaccine. Although the treatment regimen has not yet been tested, we feel it is justified to use this vaccination in symptomatic people and those with a very high risk of rabies exposure." - Anonymous Online Contributor
"Chad155-rg is one of the lead candidate antigens selected for developing a vaccine against rabies. This phase I trial provides preliminary evidence that the protocol is safe and feasible in healthy human volunteers. The potential for the vaccine to protect against rabies is also under evaluation. In conjunction with additional preclinical studies, this trial may enable development of a recombinant rabies vaccine that is both effective for prevention of rabies and suitable for use in developing countries without access to modern diagnostic tools. (https://clinicaltrials.gov/ct/show/NCT00251278) ClinicalTrials.gov, National Institutes of Health, Bethesda, MD." - Anonymous Online Contributor
"This is the first report of the successful and long term survival of two of our patients who received chad155-rg-therapeutic infusions. Chad155-rg may be a therapeutic option to prevent and manage rabies in the patient population currently unprotected." - Anonymous Online Contributor
"In the context of a rabies serosurvey, the presence of other diseases that can cause similar clinical profiles is an important issue. Data from a recent study indicates the need for more comprehensive education, which aims to identify the right diagnosis to provide care early." - Anonymous Online Contributor
"Rabics patients often do not make it to a hospital. A full spectrum of rabics treatment should be performed early in the course of their illness: [treatment with a monoclonal antibody; dosing of high dose cortics and antitransfusion [blood-transfusion]; dosing of supportive therapies such as vasopressors, diuretics, and inotropes (e.g." - Anonymous Online Contributor